Study Summary
The purpose of this study is to evaluate the safety and tolerability of CD19-Directed Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia（ALL）.
Want to learn more about this trial?
Request More InfoInterventions
alloCART-19GENETIC
AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.
* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg
* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells.
CyclophosphamideDRUG
Chemotherapy for lymphodepletion
FludarabineDRUG
Chemotherapy for lymphodepletion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Fudan University | Shanghai | Minhang | China |